2-(二乙氨基)-N-(2-甲基苯基)乙酰胺 | 3213-14-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(二乙氨基)-N-(2-甲基苯基)乙酰胺
• 英文名称: 2-(diethylamino)-N-(2-methyl-phenyl)acetamide
• 英文别名: 2-(diethylamino)-N-(2-methylphenyl)acetamide；N,N-diethyl-glycine o-toluidide；N,N-Diaethyl-glycin-o-toluidid；ω-Diethylamino-2-methylacetanilid；N,N-Diaethylamino-essigsaeure-o-toluidid；N-(Diethylamino-acetyl)-o-toluidin；o-ACETOTOLUIDIDE, 2-DIETHYLAMINO-
• CAS: 3213-14-7
• 化学式: C₁₃H₂₀N₂O
• mdl: MFCD00496541
• 分子量: 220.315
• InChiKey: DMRSJQHLNFZQHW-UHFFFAOYSA-N

物化性质

• 沸点：
  159-160 °C(Press: 0.1 Torr)
• 密度：
  1.038±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(二乙氨基)-N-(2-甲基苯基)乙酰胺 在 硝酸 作用下， 以 乙醇 为溶剂， 反应 0.08h， 以78.5%的产率得到2-(diethylamino)-N-(2-methylphenyl)acetamide nitrate
  参考文献：
  名称：

  Synthesis and Quantification of 2-(Diethylamino)-N-(2-methylphenyl)acetamide Nitrate

  摘要：

  A procedure for the synthesis of 2-(diethylamino)-N-(2-methylphenyl) acetamide nitrate (monomecaine) exhibiting a pronounced antiarrhythmic activity has been optimized. A procedure for its identification and quality control of the drug substance by HPLC has been developed, and the limit of detection of o-toluidine impurity therein has been estimated at 0.02%. Procedures for HLPC and extraction-titration quantification of monomekain in the drug substance have been proposed and validated. The obtained relative standard deviation (RSD) indicates good specificity, linearity, and precision of the developed procedures.

  DOI：

  10.1134/s1070428019100117
• 作为产物：
  描述：

  邻甲苯胺 以 苯 为溶剂， 反应 5.0h， 生成 2-(二乙氨基)-N-(2-甲基苯基)乙酰胺
  参考文献：
  名称：

  Synthesis and Quantification of 2-(Diethylamino)-N-(2-methylphenyl)acetamide Nitrate

  摘要：

  A procedure for the synthesis of 2-(diethylamino)-N-(2-methylphenyl) acetamide nitrate (monomecaine) exhibiting a pronounced antiarrhythmic activity has been optimized. A procedure for its identification and quality control of the drug substance by HPLC has been developed, and the limit of detection of o-toluidine impurity therein has been estimated at 0.02%. Procedures for HLPC and extraction-titration quantification of monomekain in the drug substance have been proposed and validated. The obtained relative standard deviation (RSD) indicates good specificity, linearity, and precision of the developed procedures.

  DOI：

  10.1134/s1070428019100117

文献信息

• Synthesis and antispasmodic activity of lidocaine derivatives endowed with reduced local anesthetic action
  作者：Jorge C.S. Costa、Josiane S. Neves、Marcus V.N. de Souza、Rodrigo A. Siqueira、Nelilma C. Romeiro、Nubia Boechat、Patrícia M.R.e Silva、Marco A. Martins

  DOI：10.1016/j.bmcl.2007.11.122

  日期：2008.2

  relationship (SAR) study focused on chemical modifications of the structure of the local anesthetic lidocaine, and indicated analogues having reduced anesthetic potency, but with superior potency relative to the prototype in preventing anaphylactic or histamine-evoked ileum contraction. From the SAR analysis, 2-(diethylamino)-N-(trifluoromethyl-phenyl) and 2-(diethylamino)-N-(dimethyl-phenyl) acetamides were

  目前的结构-活性关系（SAR）研究集中于局部麻醉利多卡因结构的化学修饰，并指出麻醉药效价降低，但与原型药相比在预防过敏或组胺引起的回肠收缩方面的效价更高。从SAR分析中，选择2-（二乙基氨基）-N-（三氟甲基-苯基）和2-（二乙基氨基）-N-（二甲基-苯基）乙酰胺作为最有前途的化合物。提供了关于非麻醉性利多卡因衍生物作为变应性综合征药物发现模板的适用性的新见解。
• Erdtman; Loefgren, Svensk Kemisk Tidskrift, 1937, vol. 49, p. 163,170,171
  作者：Erdtman、Loefgren

  DOI：——

  日期：——
• OCT3 transporters expressed in blood brain barrier cells
  申请人：Zerangue Noa

  公开号：US20070054323A1

  公开（公告）日：2007-03-08

  OCT3 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the OCT3 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
• US9968589B2
  申请人：——

  公开号：US9968589B2

  公开（公告）日：2018-05-15